Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
CAPS Rating:
The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.
RSS Headlines
Fool UK
Recs
I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!